clinical trial · NCT05750589
Safety and Tolerability of IRX-101 in Patients Receiving Intravitreal Injections
iRenix Medical, Inc.·phase3·not yet recruiting·n = 240
Retinal DiseaseIRX-101Providone-Iodine
brief summary
This is a randomized, double-masked study to evaluate the tolerability and safety of IRX-101 versus 5% povidone-iodine (PI) in subjects receiving intravitreal anti-VEGF injections.
started
Sep 1, 2026
primary completion
Jan 31, 2027
completion
Dec 31, 2027
last updated
Apr 3, 2026
official title
Randomized, Controlled, Double-Masked Study to Evaluate the Efficacy of IRX-101 in Reducing Post-Intravitreal Pain and Corneal Epitheliopathy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol